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Received January 17, 2014; accepted August 5, 2014AbstractA systematic review of genetic studies of thyroid disorders in Taiwan identified studies of gene mutations involved in the synthesis and
binding of thyroid hormone, as well as mutations of proto-oncogenes and tumor suppressor genes in thyroid cancer. Studies related to gene
polymorphisms in patients with autoimmune thyroid disease (AITD) and thyroid cancer were also reviewed. The most prevalent mutations in the
Han-Chinese population were c.2268insT in the thyroid peroxidase (TPO) gene and c.919-2A>G in the Pendred syndrome (PDS ) gene.
Additional mutations have also been revealed in the genes encoding TPO (n ¼ 5), thyroglobulin (TG; n ¼ 6), pendrin (n ¼ 2), and thyroxine-
binding globulin (TBG; n ¼ 2), which were novel at the time they were reported. The prevalence of various somatic mutations in differentiated
thyroid cancer was similar in Taiwan and Western countries, with the RAS kinase mutation and tyrosine receptor kinase (TRK ) and rearranged
during transfection (RET ) proto-oncogenes being detected in lower frequencies and the B-type RAF kinase (BRAF ) mutation accounting for the
majority of cases. Recent microRNA analysis revealed an association between miR146b and the BRAF mutation, which was associated with
poor prognosis of papillary thyroid carcinoma (PTC). Susceptibility to Graves' disease (GD) was linked to the human leukocyte antigen (HLA)
region. The associated alleles were different in Han-Chinese and Caucasians; HLA-DPB1*0501, the major allele in Taiwan, has a low frequency
in the West. By contrast, a high frequency of HLA-DRB1*0301 was detected in Caucasians but not Han-Chinese. In addition to the HLA region,
cytotoxic T lymphocyte-associated molecule-4 (CTLA4) gene polymorphisms þ49G>A and þ6230G>A (CT60) were positively associated with
GD. The GG genotype and G allele of single nucleotide polymorphism (SNP) þ49G>Awere also related to relapse of Graves' hyperthyroidism
after antithyroid drug withdrawal. Differences in the genetic patterns between Han-Chinese and Caucasians for some thyroid disorders suggest
the importance of variable genetic influences in different populations.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Thyroid disorders may be categorized into two general
groups, including functional disorders such as hyperthyroid-
ism and hypothyroidism, and structural abnormalities,
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Assthyroid disorders may reflect the effect of a mutation in a
single gene (e.g., monogenic) or the effects of polymorphisms
in multiple genes. Among the monogenic diseases, germline
mutations can affect thyroid hormone synthesis or thyroid
hormone binding in serum. However, somatic mutations play a
major role in thyroid neoplasia pathogenesis. Impaired syn-
thesis of thyroid hormone may result in congenital hypothy-
roidism while mutations in the genes encoding thyroid
hormone carrier proteins lead to clinically euthyroid patients
with falsely abnormal thyroid function tests. In addition, an
increased risk for autoimmune thyroid disease (AITD) or
thyroid neoplasia has been associated with genetic poly-
morphisms at various loci (Fig. 1). The current review willociation. All rights reserved.
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Fig. 1. Schematic diagram for genetic studies of thyroid disorders in Taiwan. BRAF ¼ B-type RAF kinase; CTLA-4 ¼ cytotoxic T lymphocyte-associated
molecule-4; FDH ¼ familial dysalbuminemic hyperthyroxinemia; GD ¼ Graves' disease; HLA ¼ human leukocyte antigen; HT ¼ Hashimoto thyroiditis;
MICA ¼ major histocompatibility complex class I-chain related gene A; PDS ¼ pendred syndrome/pendrin; PTC ¼ papillary thyroid carcinoma;
RET ¼ rearranged during transfection; TBG ¼ thyroxine-binding globulin; TG ¼ thyroglobulin; TPO ¼ thyroid peroxidase; TRK ¼ tyrosine receptor kinase;
TSH ¼ thyroid stimulating hormone; VEGF ¼ vascular endothelial growth factor.
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Taiwan regarding thyroid disorders to provide a basis for
further understanding of the thyroid genetics in the Han-
Chinese population.
2. Genetic basis of congenital hypothyroidism
The prevalence of congenital hypothyroidism in Taiwan
ranges from 1 in 1992 live births to 1 in 5788 live births,1,2
which is similar to the 1 in 4000 live births reported in Eu-
ropean and North American populations.3,4 Thyroid dysgen-
esis, such as agenesis, hypoplasia, ectopy, and hemiagenesis,
accounts for 80e85% of congenital hypothyroidism; thyroid
dyshormonogenesis contributes to the remaining 15e20% of
cases.5,6 Congenital hypothyroidism may be the result of
impaired thyroid stimulating hormone (TSH) signaling,
abnormal thyroid hormone synthesis, or defective thyroid
hormone action in target tissues (Fig. 2).6 The majority of
genetic studies in Taiwan have focused on germline mutations
involving the thyroid hormone synthesis pathways, such asFig. 2. Mutations that may lead to congenital hypothyroidism include those in th
synthesis of thyroid hormone, and mutations in TRa and TRb, causing defective
hormone synthesis include the NIS and pendrin for iodide trapping, TPO for f
NIS ¼ sodium iodide symporter; TG ¼ thyroglobulin; TPO ¼ thyroid peroxidase; T
TSH ¼ thyroid stimulating hormone; T3 ¼ triiodothyronine; T4 ¼ thyroxine.pendrin for the trapping of iodide into thyroid follicular cells,
and thyroid peroxidase (TPO), which regulates iodide organ-
ification by binding iodide to thyroglobulin (TG) and further
coupling to form thyroxine (T4) and triiodothyronine (T3).7e9
The severity of thyroid dyshormogenesis is based on
whether there is a total or partial defect in the organification of
iodide. Mutation in the TPO gene is the major contributing
factor for total iodide organification defect (TIOD); mutation
in the Pendred syndrome (PDS ) gene usually causes partial
iodide organification defect (PIOD).7,10 Despite an intact
thyroid hormone synthesis pathway in the thyroid follicular
cells, synthesis of thyroid hormone remains impaired in the
absence of a signal from pituitary thyroid stimulating hormone
(TSH) to a functional thyroid TSH receptor. Loss-of-function
mutations in the TSH receptor gene may induce TSH resis-
tance and subsequent congenital hypothyroidism.11 Mutations
in the thyroid hormone receptor alpha and beta have been
reported to result in impaired thyroid hormone action in target
tissues; however, we failed to identify any study in Taiwan
regarding this issue.12,13e TSH receptor causing impaired TSH signaling, mutations involved in the
thyroid hormone action in target tissues. Key elements involved in thyroid
acilitating iodide binding to TG, and further coupling to form T4 and T3.
Ra ¼ thyroid hormone receptor alpha; TRb ¼ thyroid hormone receptor beta;
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150 kilobases on chromosome 2p25.14,15 In the study by Niu
et al7 that evaluated 16 patients from 16 unrelated Taiwanese
families with thyroid dyshormogenesis, seven patients were
classified as having TIOD, and two patients had PIOD as
detected by the perchlorate discharge test. Three mutations,
including c.2268insT, c.2243delT, and p.G157C, in the TPO
gene were identified in the seven patients with TIOD; no TPO
gene mutation was detected in the two patients with PIOD.7 In
another study from Taiwan, five TPO gene mutations, including
c.2268insT, c.843delC, c.2413delC, c.1477G>A, and
c.2386G>T,were detected in five unrelated patients with TIOD.8
All of the above mutations identified in Taiwanese patients had
not been detected in other ethnic groups at the time of the report,
suggesting the heterogenic nature of TPOmutations by ethnicity.
The c.2268insT mutation was found to be the most common
mutation observed in both studies, accounting for 86% (12/14) of
the mutant alleles in the report fromNiu et al7 and 40% (4/10) of
the studied alleles inWu et al.8 A thymidine (T) insertion in exon
13 of the 2268 residue of the TPO gene may lead to a premature
stop codon, resulting in the formation of truncated polypeptides
and dysfunctional TPO enzymes.7,8 In addition to being the
cause of congenital hypothyroidism, c.2268insT was also asso-
ciatedwith transient hypothyroidismof the neonate.16Haplotype
analysis revealed that the c.2268insTmutation in Taiwanmay be
due to a founder effect.72.2. PDSThe PDS gene, also known as SLC26A4, contains 21
exons expanding 57,174 base pairs on chromosome
7q22-q31.1.17e19 This gene encodes the pendrin protein, an
anion transporter expressed in the thyroid, kidney, and inner
ear. Pendred syndrome (PS) is an autosomal recessive disorder
caused by biallelic mutations in the PDS gene, manifesting as
congenital sensorineural deafness, goiter, partial iodine
organification defect, and thyroid dysfunctions, ranging from
euthyroid to hypothyroidism.10 High heterogeneity and dif-
ferences by ethnicity were noted in the PDS mutations. Huang
et al20 recently summarized the mutation spectrum of the
SLC26A4 gene in the Chinese population. Although the great
majority of mutations found worldwide were missense muta-
tions, a single splice-site mutation of c.919-2A>G (g.IVS7-
2A>G) was reported to account for > 80% of the mutations
observed in Taiwan.21e23 Following c.919-2A>G, c.2168A>G
(p. H723R) was the second most common mutation in Han-
Chinese.20 By contrast, the p.L236P, p.T416P, IVS8þ1G>A,
p.E384G, p.L445W, p.T410M, p.G209V, p.V138F, p.Y530H,
and p.L597S mutations were more commonly detected in
Caucasians.20 In another study from Taiwan by Lai et al,23 a
missense mutation of c.1079C>T (p.A360V) in exon 9 of the
SLC26A4 gene was discovered for the first time in 2007.
Huang et al20 later identified another new splice-site mutation
of c.1263þ1G>A (g.IVS10þ1G>A) in compound heterozy-
gosity with c.1079C>T in a Taiwanese patient with PS.2.3. TGHuman TG is encoded by a large gene of 270 kilobases
that maps to chromosome 8q24 and contains a coding
sequence of 8.5 kilobases divided into 48 exons.24 Mutations
in the TG gene may result in congenital hypothyroidism,
goiter, thyroid neoplasia, or familial AITD.25 In seven
Taiwanese patients from six families with a TG defect, six
new TG gene mutations, including c.1348delT, p.R432X
(c.1351C>T), g.IVS3þ2T>G, c.1712delT, p.Q1765X
(c.5350C>T), and c.6047delA, were identified, which all led
to a premature translation termination.9 The most common
mutations were c.1348delT and p.R432X.9 The high preva-
lence of c.1348delT was thought to be due to a founder effect
by linking to a specific haplotype, and p.R432X was due to an
independently recurrent de novo mutation, suggesting a
mutational hot spot.92.4. TSH receptor mutationThe human TSH receptor gene is located on chromosome
14q31 and encodes the G-protein-coupled TSH receptor from
exons one to 10.9 Autonomous thyroid adenoma or congenital
hyperthyroidism may develop as a result of gain-of-function
mutations, and loss-of-function mutations in the TSH recep-
tor gene are the most common cause of TSH resistance.26
Systematic analysis of the TSH receptor gene in Japanese
patients with congenital hypothyroidism revealed a particu-
larly prevalent variant c.1349G>A (p.R450H) as the cause of
loss-of-function TSH receptor mutations.27 This mutation was
also shown to be important in Taiwanese children with
congenital hypothyroidism.28
3. Genetic alterations affecting thyroid hormone binding
The physiologically active forms of the thyroid hormones,
free T4 and free T3, account for around 0.3% of the circulating
thyroid hormones; the remaining 99.7% are bound to carrier
proteins, including thyroxine-binding globulin (TBG; 70%),
albumin (15e20%), and transthyretin (10e15%). Patients with
carrier protein gene mutations are clinically euthyroid but
laboratory abnormal and are often misdiagnosed as having
thyroid dysfunction.29,30 In patients with familial dysalbumi-
nemic hyperthyroxinemia (FDH), serum albumin exhibits
increased binding affinity to T4, causing free T4 and total T4
concentrations to be elevated as detected by the one-step
analog method but normal using the equilibrium dialysis or
two-step methods.31,32 In TBG deficiency, a low concentration
of total T4 and total T3 may result in the misdiagnosis of
hypothyroidism if free T4 was not measured simultaneously or
subsequently, resulting in unwarranted treatment with anti-
thyroid drug or thyroid hormone replacement.303.1. FDHThe human albumin gene is located within q11-22 of
chromosome 4 and contains 15 exons split by 14 intervening
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mutation in codon 218 of the albumin gene, which causes a
substitution of histidine (CAC) or proline (CCC) for arginine
(CGC).34,35 The first Chinese case of FDH with guanine (G) to
adenosine (A) transition in the second nucleotide of codon 218
of the albumin gene was reported in 1999.29 This missense
mutation is the same as that described frequently in Western
white families, but differs from the one found in a Japanese
kindred analysis.34,353.2. TBG deficiencyFig. 3. The MAPKePI3KeAKT pathway. AKT ¼ protein kinase; BRAF ¼ B-
type RAF kinase; ERK ¼ extracellular signal-regulated kinase;
MAPK ¼ mitogen activated protein kinase; MEK ¼ mitogen extracellular
kinase; PI3K ¼ phosphatidylinositol-3 kinase; PTC ¼ papillary thyroid car-
cinoma; PTEN ¼ phosphatase and tensin homolog; RET ¼ rearranged during
transfection; TRK ¼ tyrosine receptor kinase.TBG is encoded by the TBG gene on Xq22 chromosome
and consists of five exons spanning 5.5 kbp.36,37 TBG anom-
alies are transmitted through an X-linked fashion and produce
the following three clinical phenotypes determined by the
serum levels of TBG: complete TBG deficiency, partial TBG
deficiency, and TBG excess.38,39 Complete TBG deficiency is
caused by either early termination of translation or an amino
acid substitution, resulting in secretion failure.40,41 In the
report by Su et al,30 two TBG gene mutations, which were
novel at that time, were discovered in two cases of complete
TBG deficiency in Taiwan. In one case, a missense mutation,
p.S52N, consisting of a G to A transition in codon 52, resulted
in the substitution of serine (AGC) for asparagine (AAC). In
the other case, a nonsense mutation, p.W280X, consisting of a
G to A transition in codon 280 (TGG/TGA) resulted in
premature termination of translation and therefore, a truncated
protein.30
4. Somatic mutations in thyroid cancer
Thyroid cancers arising from thyroid epithelial cells
include the differentiated thyroid cancers papillary thyroid
carcinoma (PTC), follicular carcinoma, and poorly differen-
tiated carcinoma, and the undifferentiated thyroid cancer
anaplastic thyroid carcinoma (ATC). PTC and follicular car-
cinoma account for > 90% of thyroid cancers and generally
carry a favorable prognosis with 10-year survival rates of 93%
and 85%, respectively.42 By contrast, patients with ATC have a
median survival of < 6e8 months.43
Our current understanding of the molecular pathogenesis of
thyroid cancer resulted from identification of genetic and
epigenetic alterations in various signaling pathways, including
the mitogen activated protein kinase (MAPK), the
phosphatidylinositol-3 kinase (PI3K)eprotein kinase (AKT),
the nuclear factor-kB (NF-kB), the Ras association domain-
containing protein 1 (RASSF1)-mammalian sterile 20
(STE20)-like protein kinase 1 (MST1)eforkhead box O3
(FOXO3), the WNT-b-catenin, the hypoxia-inducible factor
1a (HIFIa), and the TSH receptor pathways.44 Among the
various pathways, the MAPK and PI3KeAKT are the path-
ways best characterized and show promise in thyroid cancer
treatment.45 Activation of the MAPK pathway mainly drives
the development of PTC.44 By contrast, activation of the
PI3KeAKT pathway is involved in the formation of follicular
adenoma and carcinoma.44 Upon simultaneous activation ofboth pathways with an accumulation of genetic alterations,
PTC or follicular carcinoma may progress to poorly differ-
entiated carcinoma or anaplastic carcinoma.444.1. Mutations involving the MAPKePI3KeAKT
pathwayMAPKePI3KeAKT signaling is essential for maintaining
cell growth, proliferation, differentiation, and apoptosis
(Fig. 3).46 Approximately 70% of cases of PTC are related to
somatic mutations involving the RET/PTC/RAS/-
BRAF/mitogen extracellular kinase (MEK)/extracellular
signal-regulated kinase (ERK) pathway.44,47 Rearrangement of
two receptor tyrosine kinase genes, rearranged during trans-
fection (RET ) and neurotrophic tyrosine kinase receptor type
1 (NTRK1), are specifically expressed in PTC.48,49 The fre-
quency of RET/PTC rearrangement ranges from 55%
(n ¼ 6/11) as reported by Lee et al50 to 8% (n ¼ 8/105) in Liu
et al.51 After comparing its prevalence, which ranges from 0%
to 20% worldwide,52e54 we think that the RET/PTC may not
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the chimeric gene resulting from NTRK1 rearrangement, the
TRK proto-oncogene, was not detected in 40 thyroid tumors
isolated from patients in Taiwan, suggesting that the preva-
lence of TRK mutation is even lower than RET/PTC rear-
rangement in Taiwan.51,55 In a study of 89 thyroid tumors, four
RAS mutations were detected in follicular carcinoma (n ¼ 3)
and follicular adenoma (n ¼ 1); however, they were absent in
the papillary carcinomas analyzed, suggesting that its occur-
rence differs by tumor type.56
In contrast to the low occurrence of RET/PTC rearrange-
ment and the TRK and RAS mutations in Taiwan, the BRAF
mutation was reported to be the most prevalent mutation in
PTCs and found exclusively in thyroid cancers arising from
papillary cells.47,57,58 The heterozygous mutation c.T1799A
(p.V600E) in exon 15 of the BRAF gene was detected in 49 of
105 (47%) sporadic cases of PTC in Taiwan,57 which was a
similar frequency to that reported from other geographical
areas.59e61 Recent meta-analysis suggested a positive corre-
lation between BRAF mutation and high-risk clinicopatho-
logical features of PTC, such as extrathyroid invasion, lymph
node metastasis, and advanced tumor stage.62 However,
inconsistency exists in the literature,47 and no correlation was
found in a study conducted in Taiwan.57 Recent studies on
microRNA deregulation have demonstrated an association of
specific microRNAs, particularly miR-146b, with the aggres-
siveness and prognosis of PTC,63,64 which may be related to
increased cell proliferation, migration, invasion, or resistance
to chemotherapy-induced apoptosis in response to aberrant
microRNA expression.644.2. Mutations outside the MAPK pathwayIn addition to mutations related to the MAPK pathway,
other genetic alterations have been postulated to have a role in
the pathogenesis of thyroid cancer, including those affecting
the p53, phosphatase and tensin homolog (PTEN ), and fragile
histidine triad protein (FHIT ) genes.65e67 It is understood that
p53 suppresses growth in normal cells; its inactivation is
associated with colon, lung, breast, and thyroid cancer
development.68 In Taiwan, mutations in the p53 gene have
been detected in five of 29 (17.2%) cases of poorly differen-
tiated carcinomas, two of 41 (5.0%) cases of well-
differentiated papillary carcinoma, and one of six (16.7%)
cases of oncocytic carcinoma of the thyroid.65 Consistent with
the results of other reports, the p53 gene mutations identified
included single nucleotide changes, resulting in missense or
nonsense mutations.65
Germline mutations in the PTEN tumor suppressor gene
occur often in Cowden syndrome, a syndrome characterized
by multiple tumor-like harmatomas and an increased risk of
certain cancers, such as breast, endometrial, and thyroid
follicular carcinomas.69 However, somatic mutation of the
PTEN gene was not found in any of the 17 sporadic thyroid
tumors studied in Taiwan, indicating that the PTEN gene may
not play a major role in sporadic thyroid tumors.66 With
complete sequencing of the FHIT gene, deletions betweenexons 2 and 9 were found in seven cases of thyroid tumors in
Taiwan, suggesting that FHIT gene alterations may have a role
in the formation of thyroid neoplasm.674.3. Mutation analysis in anaplastic thyroid carcinomaMutation analysis of 16 anaplastic thyroid carcinoma pa-
tients in Taiwan revealed five (5/16, 31%) cases with an N-
RAS mutation and one (1/16, 6%) case with a BRAF muta-
tion.70 While the current understanding is that accumulation
mutations in both the MAPK and PI3KeAKT pathways may
result in anaplastic thyroid carcinoma, this disease may arise
more often from RAS-mutant tumors than from BRAF-mutant
tumors.704.4. Genetics of medullary thyroid carcinomaMedullary thyroid carcinomas (MTCs) derive from paraf-
ollicular calcitonin-producing C-cells originating from the
neural crest.71 MTC is a type of neuroendocrine tumor that
possesses distinct clinical and pathological characteristics
from differentiated thyroid cancers.71 The genetic basis of
MTC is different from that of the differentiated thyroid can-
cers due to its association with multiple endocrine neoplasia
(MEN) and familial MTC syndrome.72 Mutations in the RET
proto-oncogene were detected in > 95% of patients with MTC
with MEN type 2 (MEN-2), but the frequency dropped to
around 50% in sporadic MTCs.72 Consistent with the results
reported for Western countries, mutation analysis of the RET
proto-oncogene in sporadic and MEN-associated MTC in
Taiwan revealed two common mutation sites at codon 634,
causing a substitution of cysteine to arginine or phenylalanine
(p.C634R, p.C634Y), and at codon 918, resulting in methio-
nine to threonine replacement (p.M918T).73e75 Furthermore,
in cytomorphology analysis of MTCs using fine needle aspi-
ration specimens, codon 634 mutations were more strongly
associated with small/round or large/oval to polygonal cells,
while codon 918 mutations were more related to small/round
and spindle shape cells.75
5. Polymorphism studies in thyroid cancer
In Taiwan, gene polymorphisms of the vascular endothelial
growth factor (VEGF ) gene, genes of the BER (base excision
repair) pathway, and the glutathione peroxidase 3 (GPX3)
gene have been studied in thyroid cancer.76e79 VEGF acts
through the transmembrane fms-like tyrosine kinase (FLT)
receptor family to influence cell proliferation, migration, and
angiogenesis; it also plays an important role in thyroid cancer
cell growth and distant metastasis.76 Analysis of functional
single nucleotide polymorphisms (SNPs) of VEGF in Taiwan
disclosed that the A allele of K2578C/A (i.e., SNP rs699947)
was associated with an increased risk of thyroid cancer and
regional lymph node metastasis in men.77 Alterations in genes
associated with the BER pathway, one of the DNA repair
pathways, are also hypothesized to have a role in carcino-
genesis.78 The X-ray repair cross complementing one
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functional polymorphism of one of the BER genes, were
related to thyroid cancer development and progression in
Taiwan.78 Moreover, gene polymorphism of the antioxidant
enzyme GPX3 has also been analyzed; the C allele of
rs8177412 was suggested to confer an increased risk for the
development of differentiated thyroid cancer as compared to
the T allele of rs8177412.79
6. Genetic predisposition to AITD6.1. Susceptible loci in the human leukocyte antigen
regionGenetic predisposition to AITD has been linked to a sus-
ceptible gene locus in the human leukocyte antigen (HLA)
region and in non-HLA regions, including the cytotoxic T
lymphocyte-associated molecule-4 (CTLA-4), CD40, protein
tyrosine phosphatase-22 (PTPN22), TG, and thyroid stimu-
lating hormone receptor (TSHR) genes in Caucasians.80
Linkage analysis revealed a positive association between
Graves' disease (GD) and the HLA region in a Taiwanese
population.81 HLA-DR2 and DR9 were the first two associated
alleles found.82 HLA-B*4601, the predominant allele across
Asian countries, was also reported to be a susceptible allele for
both GD and Hashimoto thyroiditis (HT) in Taiwan.83,84 Other
dominant genes in different populations included HLA-
A*0207 in adult GD patients and HLA-DRB1*0901 in chil-
dren with GD.83,85 More comprehensive HLA genotyping
performed recently in Taiwan identified susceptible alleles
with independent effects, including HLA-B*4601, HLA-
DPB1*0501, DRB1*1502, and 1602.84 Specifically, whereas
DRB1*1202 and DQB1*0302 conferred a protective effect for
GD, a high frequency of HLA-DRB1*0301 was detected in
Caucasians with GD, and HLA-DPB1*0501 was shown to be
the major allele associated with GD in Taiwan.846.2. CTLA-4 gene in GDCTLA-4 functions as a T cell regulator, inhibiting T cell
activation possibly through interfering with the costimulatory
effect of CD28.86 Meta-analysis of CTLA-4 gene poly-
morphisms has showed a positive association of two SNPs,
þ49G>A and þ6230G>A (CT60), with AITD.86 In a
Taiwanese population, the GG genotype and G allele of SNP
CT60 was associated with susceptibility to GD in adults and
children.87,88 Besides the association with GD, the GG geno-
type and G allele of SNP þ49G>Awas also related to relapse
of Graves' hyperthyroidism after withdrawal of antithyroid
drugs.89,90 Similar to the antigen presentation and T cell
activation function of major histocompatibility complex
(MHC), MHC class I-chain related gene A (MICA) functions
as a stress-induced antigen and ligand for natural killer (NK)
cell activation.91 Microsatellite repeat polymorphism within
the transmembrane region of MICA varied between in-
dividuals.91 In children with GD, Lo et al91 found that allele
A5 was associated with higher risk for the development of GD.6.3. Cytokine gene polymorphism and AITDAssociation-related studies of cytokine gene polymorphism
in AITD are discrepant.92e100 In Taiwan, a positive association
with GD was found in the allelic variants of the interleukin-1-
b (IL-1-b) gene promoter (G-511C) and the tumor necrosis
factor-a (TNF-a) gene promoter (G-238A and G-308A), but
not the IL-1 receptor antagonist (IL-1RA) gene, the IL-8 30
untranslated region (30-UTR), or the IL-4, IL-6, and IL-10 gene
promoters.93e96 In addition, a meta-analysis of eight studies
by Lee et al97 reported no association between IL-4 gene SNPs
and GD. However, a TA haplotype of the IL-4 gene conferred
risk for GD, suggesting that the haplotype-based method may
be more powerful in studying geneedisease associations than
individual SNPs.976.4. Other studies on HTThe number of genetic studies on HT was much lower than
that of GD in Taiwan. In addition to the aforementioned
positive association of HLA-B*4601 with HT, the C/G geno-
type and allele C of SNP rs187238 in the IL-18 gene conferred
an increased risk in children.98 Analysis of four common
polymorphisms of the vitamin-D receptor (VDR) gene,
including FokI (rs10735810), TaqI (rs731236), BsmI
(rs1544410), and ApaI (rs7975232), suggested that the ho-
mozygous C/C VDR-FokI gene polymorphism in exon 2
conferred a higher risk of developing HT in Chinese patients.99
However, a recent meta-analysis suggested that the BsmI and
TaqI polymorphisms were more strongly associated with
AITD, whereas ApaI or FokI polymorphisms were not.100
In conclusion, the mutation spectrum of the Han-Chinese
population observed in monogenic thyroid disorders was
different from that of Caucasians. The single most common
mutation in the TPO gene, c.2268insT, was observed in more
than half of the cases of congenital hypothyroidism with TPO
gene mutation in Taiwan. In the PDS gene, IVS7-2A>G
(c.919-2A>G) accounted for > 80% of the mutations in the
Han-Chinese population. All of the six mutations identified in
the TG gene were novel, suggesting that there may be a
distinct mutation spectrum in the Taiwanese population. By
contrast, the epidemiology of different somatic mutations in
differentiated thyroid cancer in Taiwan was similar to that of
Western countries, with most of the mutations involving the
MAPK pathway in a prevalent sequence of BRAF occurring
more often than RAS, RET/PTC, and TRK mutations. In spo-
radic and MEN-associated MTC in Taiwan, two common
mutation sites in the RET proto-oncogene at codons 634 and
918 were observed, which is consistent with results from other
populations.
In genetic studies of AITDs, different dominant HLA al-
leles in Asians or Caucasians with GD were disclosed; HLA-
DPB1*0501 was found in high frequency in Asian countries
but not in the West. In addition, two SNPs of the CTLA-4
gene, þ49G>A and þ6230G>A (CT60), were positively
associated with GD in Taiwan. Analysis of cytokine genes in
Taiwan as well as in other populations has been conflicting.
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suggest that specific genetic patterns exist in some diseases in
Han-Chinese whereas others were similar to the results
observed worldwide.
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